Apollo Endosurgery Inc (NASDAQ:APEN) Director Matthew S. Crawford acquired 4,038 shares of the stock in a transaction on Friday, March 9th. The shares were purchased at an average price of $6.20 per share, for a total transaction of $25,035.60. Following the completion of the transaction, the director now owns 53,715 shares in the company, valued at approximately $333,033. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Apollo Endosurgery Inc (APEN) traded up $0.06 during trading on Friday, reaching $6.40. 2,977 shares of the company’s stock traded hands, compared to its average volume of 40,961. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.23 and a quick ratio of 1.68. The company has a market capitalization of $113.26, a PE ratio of -2.95 and a beta of 0.46. Apollo Endosurgery Inc has a 1 year low of $3.55 and a 1 year high of $14.09.
Apollo Endosurgery (NASDAQ:APEN) last released its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.08). Apollo Endosurgery had a negative net margin of 42.35% and a negative return on equity of 64.48%. The company had revenue of $16.14 million for the quarter, compared to the consensus estimate of $16.64 million. equities analysts expect that Apollo Endosurgery Inc will post -1.41 EPS for the current fiscal year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC bought a new stake in shares of Apollo Endosurgery during the third quarter valued at approximately $11,067,000. King Luther Capital Management Corp acquired a new position in Apollo Endosurgery in the third quarter valued at approximately $2,567,000. Russell Investments Group Ltd. acquired a new position in Apollo Endosurgery in the third quarter valued at approximately $1,288,000. Woodmont Investment Counsel LLC acquired a new position in Apollo Endosurgery in the third quarter valued at approximately $220,000. Finally, JPMorgan Chase & Co. acquired a new position in Apollo Endosurgery in the third quarter valued at approximately $119,000. 31.27% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have recently commented on APEN shares. Northland Securities restated a “buy” rating and set a $12.00 price target on shares of Apollo Endosurgery in a report on Monday, December 4th. Roth Capital set a $10.00 price objective on shares of Apollo Endosurgery and gave the stock a “buy” rating in a report on Thursday, January 4th. Zacks Investment Research lowered shares of Apollo Endosurgery from a “buy” rating to a “hold” rating in a research report on Wednesday, December 27th. Finally, ValuEngine raised shares of Apollo Endosurgery from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $9.44.
COPYRIGHT VIOLATION WARNING: “Apollo Endosurgery Inc (NASDAQ:APEN) Director Purchases $25,035.60 in Stock” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/03/23/insider-buying-apollo-endosurgery-inc-apen-director-buys-25035-60-in-stock.html.
Apollo Endosurgery Company Profile
Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.
Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.